Most importantly, intrathecal delivery of Fto-shRNA to knock down Fto, an m6A eraser enzyme, ameliorated the motor deficits of SOD1G93A mice (an ALS mouse model) and extended their lifespan. This evidence concerns the gene METTL3 and amyotrophic lateral sclerosis.